ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Epilepsy-induced heart damage and sudep risk: ion channelopathies, calcium homeostasis, and the therapeutic potential of resveratrol.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Resveratrol's Neuroprotective Effects on the Retina in a Pentylenetetrazol-Induced Epilepsy Model in Rats: Insights into SIRT1 Signaling, Apoptosis, and Gliosis.Antioxidants (Basel, Switzerland) · 2026Article
- Zinc Supplementation Sustains Diaphragm Contractility and PreservesBiomolecules · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy is a worldwide health issue associated with cardiac-related conditions and Sudden Unexpected Death in Epilepsy (SUDEP). The pathophysiology of SUDEP involves structural fibrosis of the myocardium, a calcium imbalance, and dysfunction of the autonomic nervous system. The objective of this investigation was to examine cardiac damage resulting from epilepsy triggered by the Pentylenetetrazol (PTZ) kindling rat model at a dosage of 35 mg/kg administered intraperitoneally, and to assess the therapeutic benefits of Resveratrol (RSV) at a dosage of 5 mg/kg. Cardiac function was evaluated using isolated papillary muscle recordings. Damage to the structure was assessed by Sirius Red staining and general tissue morphology. Molecular analyses encompassed qPCR (SERCA2a, CACNA1G, HCN2, CAS3/9) and immunofluorescence (SIRT1, Caspase-3, S100α) in conjunction with the total Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.